หน้าแรก
ค้นหา
Dr. Hamilton on the Optimal Duration of Trastuzumab in HER2+ Breast Cancer
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Hamilton on the Optimal Duration of Trastuzumab in HER2+ Breast Cancer
Dr. Hamilton Discusses Challenges With Approved Treatments for HER2-Positive Breast Cancer
Dr. Hamilton on the HER2CLIMB Trial in Metastatic HER2+ Breast Cancer
Dr. Hamilton on How Neratinib Targets HER2+ Breast Cancer
Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast Cancer
Dr. Erika P. Hamilton on ONT-380 in HER2-Positive Breast Cancer Patients With Brain Metastases
Dr. Hamilton on the FDA Approval of Tucatinib in HER2+ Breast Cancer
Dr. Hamilton on Using pCR to Classify Risk in HER2+ Breast Cancer
Dr. Pegram Discusses Adjuvant Pertuzumab in HER2+ Breast Cancer
Dr. Kimberly L. Blackwell on a Promising HER2+ Breast Cancer Treatment
Sequencing HER2-targeted therapies in breast cancer
HER2CLIMB-05: tucatinib + trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic BC
APHINITY Trial: Adjuvant Pertuzumab and Trastuzumab
PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer
Dr. Park on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer
Choosing between tucatinib and T-DXd in HER2+ breast cancer
ONT-380 in Combination With Capecitabine and Trastuzumab in HER2-Positive Breast Cancer
Diarrhea Management in HER2+ Breast Cancer
Dr. Vidal on Potential of [Fam-] Trastuzumab Deruxtecan in HER2+ Breast Cancer
Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research
